368 Extent of Vascular Dysregulation in Diffuse Gliomas is Determined by IDH1 Mutation Status

Neurosurgery ◽  
2017 ◽  
Vol 64 (CN_suppl_1) ◽  
pp. 286-286
Author(s):  
Zachary K Englander ◽  
Craig I Horenstein ◽  
Stephen G Bowden ◽  
Marc Louis Otten ◽  
Angela Lignelli ◽  
...  

Abstract INTRODUCTION Mutation of the isocitrate dehydrogenase 1 (IDH1) gene is an important prognostic marker in diffuse gliomas. IDH1 wild-type tumors have worse clinical outcomes and more invasive imaging features than their IDH1 mutant counterparts. However, the degree of glioma infiltration outside radiologically-defined tumor borders has not been quantified. Blood oxygenation level dependent (BOLD) fMRI can detect glioma-induced disruption of normal vascular regulatory function that occurs beyond conventional tumor margins. The present study quantifies the spatial extent of vascular dysregulation associated with IDH1 mutation status in patients with treatment-naïve diffuse gliomas. We hypothesized that IDH1 wild-type gliomas will have larger areas of BOLD signal abnormality in the surrounding brain tissue and will ultimately demonstrate greater residual disease following surgical resection of the tumor. METHODS BOLD maps of vascular dysregulation were generated from preoperative fMRI scans of 34 treatment-naïve patients with WHO grades II-IV gliomas. IDH1 mutation status was determined by immunohistochemical staining for the mutant IDH1 R132H protein. We directly compared the spatial overlap of vascular dysregulation measured by BOLD fMRI and the radiologically-defined tumor using the Dice coefficient. We also performed a regression analysis to compare the relationship between percent of tumor resected and fraction of residual BOLD abnormality. RESULTS >The BOLD abnormality extended further beyond the tumor margins in IDH1 wild-type gliomas than in IDH1 mutants (P = 2 × 10−8). Furthermore, after controlling for patient age, histological subtype, WHO grade, and 1p/19q co-deletion status, IDH1 mutation status remained a significant predictor of the extent of vascular dysregulation beyond the tumor margins (P = 0.0001). Finally, surgical resection eliminated a smaller fraction of the BOLD abnormality in IDH1 wild-type tumors (P = 0.0016). CONCLUSION IDH1 mutation status is a critical variable affecting extent of infiltration and the volume of residual disease following surgical resection. BOLD fMRI may be clinically useful for guiding extent of resection in diffuse gliomas.

2019 ◽  
Vol 18 ◽  
pp. 153601211989408
Author(s):  
Nijiati Kudulaiti ◽  
Huiwei Zhang ◽  
Tianming Qiu ◽  
Junfeng Lu ◽  
Abudumijiti Aibaidula ◽  
...  

Purpose: We evaluated the relationship between isocitrate dehydrogenase 1 (IDH1) mutation status and metabolic imaging in patients with nonenhancing supratentorial diffuse gliomas using 11C-methionine positron emission tomography (11C-MET PET). Materials and Methods: Between June 2012 and November 2017, we enrolled 86 (38 women and 48 men; mean age, 41.9 ± 13.1 years [range, 8-67 years]) patients with newly diagnosed supratentorial diffuse gliomas. All patients underwent preoperative 11C-MET PET. Tumor samples were obtained and immunohistochemically analyzed for IDH1 mutation status. Results: The mutant and wild-type IDH1 diffuse gliomas had significantly different mean maximum standardized uptake value values (2.73 [95% confidence interval, CI: 2.32-3.16] vs 3.85 [95% CI: 3.22-4.51], respectively; P = .004) and mean tumor-to-background ratio (1.90 [95% CI: 1.65-2.16] vs 2.59 [95% CI: 2.17-3.04], respectively; P = .007). Conclusions: 11C-methionine PET can noninvasively evaluate the IDH1 mutation status of patients with nonenhancing supratentorial diffuse gliomas.


2016 ◽  
Vol 124 (6) ◽  
pp. 1611-1618 ◽  
Author(s):  
Abudumijiti Aibaidula ◽  
Wang Zhao ◽  
Jin-song Wu ◽  
Hong Chen ◽  
Zhi-feng Shi ◽  
...  

OBJECT Conventional methods for isocitrate dehydrogenase 1 (IDH1) detection, such as DNA sequencing and immunohistochemistry, are time- and labor-consuming and cannot be applied for intraoperative analysis. To develop a new approach for rapid analysis of IDH1 mutation from tiny tumor samples, this study used microfluidics as a method for IDH1 mutation detection. METHODS Forty-seven glioma tumor samples were used; IDH1 mutation status was investigated by immunohistochemistry and DNA sequencing. The microfluidic device was fabricated from polydimethylsiloxane following standard soft lithography. The immunoanalysis was conducted in the microfluidic chip. Fluorescence images of the on-chip microcolumn taken by the charge-coupled device camera were collected as the analytical results readout. Fluorescence signals were analyzed by NIS-Elements software to gather detailed information about the IDH1 concentration in the tissue samples. RESULTS DNA sequencing identified IDH1 R132H mutation in 33 of 47 tumor samples. The fluorescence signal for IDH1-mutant samples was 5.49 ± 1.87 compared with 3.90 ± 1.33 for wild type (p = 0.005). Thus, microfluidics was capable of distinguishing IDH1-mutant tumor samples from wild-type samples. When the cutoff value was 4.11, the sensitivity of microfluidics was 87.9% and the specificity was 64.3%. CONCLUSIONS This new approach was capable of analyzing IDH1 mutation status of tiny tissue samples within 30 minutes using intraoperative microsampling. This approach might also be applied for rapid pathological diagnosis of diffuse gliomas, thus guiding personalized resection.


2021 ◽  
Author(s):  
Hiroyuki Tatekawa ◽  
Hiroyuki Uetani ◽  
Akifumi Hagiwara ◽  
Shadfar Bahri ◽  
Catalina Raymond ◽  
...  

Abstract This study aimed to assess the association between biological tumor burden in pre- and post-operative status and overall survival (OS) in isocitrate dehydrogenase (IDH) wild-type gliomas, and to evaluate which volume was the best predictor of OS. Thirty-four patients with treatment-naïve IDH wild-type gliomas (grade II, 6; III, 15; IV, 13) were retrospectively included. Three pre-operative tumor regions of interest (ROIs) were segmented based on the contrast-enhanced (CE), fluid-attenuated inversion recovery (FLAIR) hyperintense, and 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (FDOPA) hypermetabolic regions. Resected ROIs were segmented from the post-operative images. Residual CE, FLAIR hyperintense, and FDOPA hypermetabolic ROIs were created by subtracting resected ROIs from pre-operative ROIs. Cox regression was conducted to investigate the association of OS with the volume of each ROI. Residual CE volume had a significant association with OS (hazard ratio [HR] = 1.26, P = 0.039), but this effect disappeared when controlling for tumor grade. Residual FDOPA hypermetabolic volume was significantly associated with OS (HR = 1.18, P = 0.008), even when controlling for tumor grade. FLAIR hyperintense volume showed no significant association with OS. Residual FDOPA hypermetabolic burden predicted OS for IDH wild-type gliomas, regardless of tumor grade. Furthermore, removing hypermetabolic and CE regions may improve the prognosis.


2019 ◽  
Vol 21 (Supplement_3) ◽  
pp. iii32-iii32
Author(s):  
H Noor ◽  
R Rapkins ◽  
K McDonald

Abstract BACKGROUND Tumour Protein 53 (TP53) is a tumour suppressor gene that is mutated in at least 50% of human malignancies. The prevalence of TP53 mutation is much higher in astrocytomas with reports of up to 75% TP53 mutant cases. Rare cases of TP53 mutation also exist in oligodendroglial tumours (10–13%). P53 pathway is therefore an important factor in low-grade glioma tumorigenesis. Although the prognostic impact of TP53 mutations has been studied previously, no concrete concordance were reached between the studies. In this study, we investigated the prognostic effects of TP53 mutation in astrocytoma and oligodendroglioma. MATERIAL AND METHODS A cohort of 65 matched primary and recurrent fresh frozen tumours were sequenced to identify hotspot exons of TP53 mutation. Exons 1 to 10 were sequenced and pathogenic mutations were mostly predominant between Exons 4 and 8. The cohort was further expanded with 78 low grade glioma fresh frozen tissues and hotspot exons were sequenced. Selecting only the primary tumour from 65 matched tumours, a total of 50 Astrocytoma cases and 51 oligodendroglioma cases were analysed for prognostic effects of TP53. Only pathogenic TP53 mutations confirmed through COSMIC and NCBI databases were included in the over survival and progression-free survival analysis. RESULTS 62% (31/50) of astrocytomas and 16% (8/51) of oligodendrogliomas harboured pathogenic TP53 mutations. Pathogenic hotspot mutations in codon 273 (c.817 C>T and c.818 G>A) was prevalent in astrocytoma with 58% (18/31) of tumours with these mutations. TP53 mutation status was maintained between primary and recurrent tumours in 93% of cases. In astrocytoma, overall survival of TP53 mutant patients was longer compared to TP53 wild-type patients (p<0.01) but was not significant after adjusting for age, gender, grade and IDH1 mutation status. In contrast, astrocytoma patients with specific TP53 mutation in codon 273 showed significantly better survival compared to other TP53 mutant and TP53 wild-type patients combined (p<0.01) in our multivariate analysis. Time to first recurrence (progression-free survival) of TP53 mutant patients was significantly longer than TP53 wild-type patients (p<0.01) after adjustments were made, while TP53 mutation in codon 273 was not prognostic for progression-free survival. In oligodendroglioma patients, TP53 mutations did not significantly affect overall survival and progression-free survival. CONCLUSION In agreement with others, TP53 mutation is more prevalent in Astrocytoma and mutations in codon 273 are significantly associated with longer survival.


Blood ◽  
2006 ◽  
Vol 108 (10) ◽  
pp. 3494-3503 ◽  
Author(s):  
Steven Knapper ◽  
Kenneth I. Mills ◽  
Amanda F. Gilkes ◽  
Steve J. Austin ◽  
Val Walsh ◽  
...  

Abstract The receptor tyrosine kinase FLT3 is a promising molecular therapeutic target in acute myeloid leukemia (AML). Activating mutations of FLT3 are present in approximately one-third of patients, while many nonmutants show evidence of FLT3 activation, which appears to play a significant role in leukemogenesis. We studied the effects of lestaurtinib (CEP701) and PKC412, 2 small molecule inhibitors of FLT3, on 65 diagnostic AML blast samples. Both agents induced concentration-dependent cytotoxicity in most cases, although responses to PKC412 required higher drug concentrations. Cytotoxic responses were highly heterogeneous and were only weakly associated with FLT3 mutation status and FLT3 expression. Importantly, lestaurtinib induced cytotoxicity in a synergistic fashion with cytarabine, particularly in FLT3 mutant samples. Both lestaurtinib and PKC412 caused inhibition of FLT3 phosphorylation in all samples. Translation of FLT3 inhibition into cytotoxicity was influenced by the degree of residual FLT3 phosphorylation remaining and correlated with deactivation of STAT5 and MAP kinase. FLT3 mutant and wild-type cases both varied considerably in their dependence on FLT3 signaling for survival. These findings support the continued clinical assessment of FLT3 inhibitors in combination with cytotoxic chemotherapy: Entry to future clinical trials should include FLT3 wild-type patients and should remain unrestricted by FLT3 expression level.


2014 ◽  
Vol 16 (6) ◽  
pp. 779-786 ◽  
Author(s):  
Anne L. Baldock ◽  
Kevin Yagle ◽  
Donald E. Born ◽  
Sunyoung Ahn ◽  
Andrew D. Trister ◽  
...  

PLoS ONE ◽  
2013 ◽  
Vol 8 (6) ◽  
pp. e66198 ◽  
Author(s):  
Jenna L. Mueller ◽  
Zachary T. Harmany ◽  
Jeffrey K. Mito ◽  
Stephanie A. Kennedy ◽  
Yongbaek Kim ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document